{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:28:43Z","timestamp":1789954123062,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ijantimicag.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T07:41:02Z","timestamp":1549006862000},"page":"637-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme"],"prefix":"10.1016","volume":"53","author":[{"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0001","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options","volume":"22","author":"Cerceo","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0002","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0004","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of multidrug-resistant Gram-negative infections in children","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0005","doi-asserted-by":"crossref","first-page":"i939","DOI":"10.1136\/bmj.i939","article-title":"Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis","volume":"352","author":"Bryce","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0006","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0007","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0008","series-title":"I. Zerbaxa (ceftolozane tazobactam) prescribing information","year":"2015"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0009","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0011","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.diagmicrobio.2013.03.032","article-title":"Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007\u20132009 SENTRY Antimicrobial Surveillance Program","volume":"76","author":"Kaiser","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0012","series-title":"Methods for dilution antimicrobial susceptibiity tests for bacteria that grow aerobically. M07","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0013","series-title":"Performance standards for antimicrobial susceptibility testing. M100","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0014","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1128\/JCM.03184-14","article-title":"Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial","volume":"53","author":"Kehl","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0000000000001859","article-title":"Ceftazidime-avibactam antimicrobial activity and spectrum when tested against Gram-negative organisms from pediatric patients: results from the INFORM Surveillance Program (United States, 2011\u20132015)","volume":"37","author":"Sader","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0017","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/INF.0b013e31828aebc8","article-title":"Antibiotic-resistant Gram-negative bacteremia in pediatric oncology patients \u2013 risk factors and outcomes","volume":"32","author":"Haeusler","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0018","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11908-016-0555-4","article-title":"Antibiotic resistance in pediatric urinary tract infections","volume":"18","author":"Stultz","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0019","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/jpids\/pit049","article-title":"Microbiological and genetic characterization of carbapenem-resistant Klebsiella pneumoniae isolated from pediatric patients","volume":"3","author":"Dara","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jpids\/piw076","article-title":"The molecular and clinical epidemiology of extended-spectrum cephalosporin- and carbapenem-resistant Enterobacteriaceae at 4 US pediatric hospitals","volume":"6","author":"Zerr","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0021","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0022","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0023","series-title":"Surveillance of antimicrobial resistance in Europe \u2013 annual report of the European Antimicrobial Resistance Sruveillance Network (EARS-Net) 2017","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0024","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/INF.0000000000002170","article-title":"Pharmacokinetics and safety of single intravenous doses of ceftolozane\/tazobactam in children with proven or suspected Gram-negative infection","volume":"37","author":"Bradley","year":"2018","journal-title":"Pediatr Infect Dis J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T17:41:53Z","timestamp":1565199713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919300226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0924857919300226"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.015","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}